Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IVF hartmann Holding AGXSWX:VBSN +0.39%73 EV-to-EBITDA is 7.37 as of Aug. 02, 2026, which is 54% below its 10-year median of 16.04. GuruFocus rates XSWX:VBSN with a GF Score™ of 73/100 and a GF Value™ of CHF143.44 (Modestly Undervalued). Among 512 Medical Devices & Instruments companies, IVF hartmann Holding AG ranks better than 78.91% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, IVF hartmann Holding AG's enterprise value is CHF193.3 Mil.
IVF hartmann Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF26.2 Mil. Therefore, IVF hartmann Holding AG's EV-to-EBITDA for today is 7.37.
The historical rank and industry rank for IVF hartmann Holding AG's EV-to-EBITDA or its related term are showing as below:
XSWX:VBSN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.92 Med: 16.04 Max: 22.79
Current: 7.38
During the past 13 years, the highest EV-to-EBITDA of IVF hartmann Holding AG was 22.79. The lowest was 6.92. And the median was 16.04.
XSWX:VBSN's EV-to-EBITDA is ranked better than 78.91% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.39
vs XSWX:VBSN: 7.38
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
IVF hartmann Holding AG (XSWX:VBSN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IVF hartmann Holding AG's PE Ratio (TTM) for today is calculated as:
IVF hartmann Holding AG's share price for today is CHF127.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. IVF hartmann Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF7.620.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:VBSN vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, IVF hartmann Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IVF hartmann Holding AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, IVF hartmann Holding AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where IVF hartmann Holding AG's EV-to-EBITDA falls into.
IVF hartmann Holding AG's current Enterprise Value is CHF193.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. IVF hartmann Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF26.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVF hartmann Holding AG (XSWX:VBSN) has a EV-to-EBITDA of 7.37 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on IVF hartmann Holding AG. This is 54% below median its historical median of 16.04. Over the past decade, IVF hartmann Holding AG's EV-to-EBITDA has ranged from 6.92 to 22.79. According to the industry distribution chart, IVF hartmann Holding AG ranks #108 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 21.1%.
Is IVF hartmann Holding AG's EV-to-EBITDA too high?
IVF hartmann Holding AG's current EV-to-EBITDA of 7.37 is 54% below median its 10-year median of 16.04. Over the past 10 years, this metric has ranged from a low of 6.92 to a high of 22.79. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.39. IVF hartmann Holding AG's value of 7.37 is 48.8% below this industry median. Based on the distribution chart, IVF hartmann Holding AG ranks #108 out of 512 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, IVF hartmann Holding AG has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IVF hartmann Holding AG's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, IVF hartmann Holding AG ranks #108 out of 512 companies for EV-to-EBITDA. This places IVF hartmann Holding AG in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.39. IVF hartmann Holding AG's value of 7.37 is 48.8% below this benchmark. Historically, IVF hartmann Holding AG's own EV-to-EBITDA has ranged from 6.92 to 22.79 over the past decade. While the company's 10-year median is 16.04 vs. the industry median of 14.39, IVF hartmann Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.39, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IVF hartmann Holding AG's current EV-to-EBITDA of 7.37 is 48.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on IVF hartmann Holding AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IVF hartmann Holding AG's current EV-to-EBITDA is 7.37, which is 54% below median its own 10-year median of 16.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IVF hartmann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, IVF hartmann Holding AG (XSWX:VBSN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF143.44, compared to a current price of CHF127.50 — trading 11.1% below its estimated fair value. The current EV-to-EBITDA is 7.37, which is 54% below median its 10-year median of 16.04 and 48.8% below the Medical Devices & Instruments industry median of 14.39. IVF hartmann Holding AG's overall GF Score™ is 73/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For IVF hartmann Holding AG (XSWX:VBSN), the current EV-to-EBITDA is 7.37 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IVF hartmann Holding AG (XSWX:VBSN) Overvalued in 2026?
Based on GuruFocus' analysis, IVF hartmann Holding AG stock appears to be undervalued.
The current stock price of CHF127.50 is trading 11.1% below its estimated GF Value™ of CHF143.44.
GuruFocus considers IVF hartmann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:VBSN:
EV-to-EBITDA: 7.37 (54% below median its 10-year median of 16.04)
GF Value™: CHF143.44 vs. price of CHF127.50 (11.1% below fair value)
Industry Position: 48.8% below the Medical Devices & Instruments median (#108 of 512)
No single metric tells the full story. See the XSWX:VBSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IVF hartmann Holding AG engages in production and supply of medical, pharmaceutical and hygiene products in Switzerland, it offers products such as surgical disposable, disposable dental, first aid, therapeutic plaster, cotton wool, wound care among others. The company operates in four segment wound care, incontinence management, infection management and Other group activities.
73GF Score
Get the complete analysis for XSWX:VBSN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:VBSN has been successfully added to your 
